IMV Commences Trading on the TSX and Nasdaq Post-Reverse Stock Split
13 Diciembre 2022 - 6:05AM
Business Wire
IMV Inc. (the “Corporation” or “IMV”) (NASDAQ: IMV; TSX: IMV), a
clinical-stage biopharmaceutical company developing a portfolio of
immune-educating therapies based on its novel DPX® platform to
treat solid and hematologic cancers, announced that its common
shares commence trading post consolidation today.
As announced and previously approved by shareholders on December
7, 2022, the Corporation has consolidated its outstanding common
shares on the basis of one new common share for every 10
outstanding common shares. The consolidation has taken effect on
December 7, 2022, and the Corporation’s common shares commence
trading on the Toronto Stock Exchange and on the Nasdaq Capital
Market (“Nasdaq”) under the name IMV Inc. on a post-consolidation
basis at the opening of markets today.
The consolidation is primarily intended to bring the Corporation
into compliance with the minimum required closing bid price for
continued listing on Nasdaq of US$1.00 per share.
About IMV
IMV Inc. is a clinical-stage immuno-oncology company advancing a
portfolio of therapies based on the Corporation’s immune-educating
platform, DPX®. Through a differentiated mechanism of action, the
DPX platform delivers instruction to the immune system to generate
a specific, robust, and persistent immune response. IMV’s lead
candidate, maveropepimut-S (MVP-S), delivers antigenic peptides
from survivin, a well-recognized cancer antigen commonly
overexpressed in advanced cancers. MVP-S also delivers an innate
immune activator and a universal CD4 T cell helper peptide. These
elements foster maturation of antigen presenting cells as well as
robust activation of CD8 T cell effector and memory function. MVP-S
treatment has been well tolerated and has demonstrated defined
clinical benefit in multiple cancer indications as well as the
activation of a targeted and sustained, survivin-specific
anti-tumor immune response. MVP-S is currently being evaluated in
clinical trials for hematologic and solid cancers, including
Diffuse Large B Cell Lymphoma (DLBCL) as well as ovarian, bladder
and breast cancers. IMV is also developing a second immunotherapy
leveraging the DPX immune delivery platform, DPX-SurMAGE. This
dual-targeted immunotherapy combines antigenic peptides for both
the survivin and MAGE-A9 cancer proteins to elicit immune responses
to these two distinct cancer antigens simultaneously. A Phase 1
clinical trial in bladder cancer, using MVP-S or DPX-SurMAGE, was
initiated in early 2022. For more information, visit
www.imv-inc.com and connect with us on Twitter and LinkedIn.
IMV Forward-Looking Statements
This press release contains forward-looking information under
applicable securities law. All information that addresses
activities or developments that we expect to occur in the future is
forward-looking information. Forward-looking statements use such
word as “will”, “may”, “potential”, “believe”, “expect”,
“continue”, “anticipate” and other similar terminology.
Forward-looking statements are based on the estimates and opinions
of management on the date the statements are made. In the press
release, such forward-looking statements include, but are not
limited to, statements regarding the Corporation’s ability to
maintain its Nasdaq listing. However, they should not be regarded
as a representation that any of the plans will be achieved. Actual
results may differ materially from those set forth in this press
release due to risks affecting the Corporation, including access to
capital, the successful design and completion of clinical trials
and the timely receipt of all regulatory approvals to commence, and
then continue, clinical studies and trials and the receipt of all
regulatory approvals to commercialize its products. IMV assumes no
responsibility to update forward-looking statements in this press
release except as required by law. These forward-looking statements
involve known and unknown risks and uncertainties, and those risks
and uncertainties include, but are not limited to, the ability to
access capital, the successful and, generally, the timely
completion of clinical trials and studies and the receipt of all
regulatory approvals as well as other risks detailed from time to
time in our ongoing quarterly filings and annual information form.
Investors are cautioned not to rely on these forward-looking
statements and are encouraged to read IMV’s continuous disclosure
documents, including its current annual information form, as well
as its audited annual consolidated financial statements which are
available on SEDAR at www.sedar.com and on EDGAR at
www.sec.gov/edgar
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221213005256/en/
Investor Relations & Media Delphine Davan, Senior
Director, Communications and Investor Relations, IMV Inc. (902)
492.1819 ext: 1049 ddavan@imv-inc.com
IMV (NASDAQ:IMV)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
IMV (NASDAQ:IMV)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024